Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Find generic entry opportunities
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Abstract:||The present invention relates to novel derivatives of exendin-4 or exendin-4 fragments, wherein the derivatives have a lipophilic substituent attached, optionally via a spacer, to an amino acid residue, which is not the N-terminal or C-terminal amino acid residue of the derivative.|
|Inventor(s):||Knudsen; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (Copenhagen K, DK), Nielsen; Per Franklin (V.ae butted.rlose, DK), Madsen; Kjeld (Vaerlose, DK)|
|Assignee:||Novo Nordisk A/S (Bagsvaerd, DK)|
|Filing Date:||Jun 21, 2001|
|Claims:||1. A derivative of exendin-4 or a fragment thereof, wherein said derivative has one lipophilic substituent attached, optionally via a spacer, to an amino acid residue of said exendin-4 or fragment thereof, which is not the N-terminal or C-terminal amino acid residue of said exendin-4 or fragment thereof, wherein said fragment has insulinotropic activity. |
2. A pharmaceutical composition comprising a derivative of claim 1 and a pharmaceutically acceptable vehicle or carrier.
3. A method of treating insulin dependent or non-insulin dependent diabetes mellitus in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a derivative of claim 1 and a pharmaceutically acceptable carrier.
4. The derivative of claim 1, wherein the lipophilic substituent has 4 to 40 carbon atoms.
5. The derivative of claim 4, wherein the lipophilic substituent has 8 to 25 carbon atoms.
6. The derivative of claim 4, wherein the lipophilic substituent is attached by means of a spacer.
7. The derivative of claim 6, wherein the spacer is an unbranched alkane .alpha.,.omega.-dicarboxylic acid group having from 1 to 7 methylene groups.
8. The derivative of claim 4, wherein the lipophilic substituent is a straight-chain or branched acyl group.
9. The derivative of claim 8, wherein the acyl group is of the formula CH.sub.3(CH.sub.2).sub.nCO--, wherein n is 4 to 38.
10. The derivative of claim 9, wherein the acyl group is CH.sub.3(CH.sub.2).sub.6CO--, CH.sub.3(CH.sub.2).sub.8CO--, CH.sub.3(CH.sub.2).sub.10CO--, CH.sub.3(CH.sub.2).sub.12CO--, CH.sub.3(CH.sub.2).sub.14CO--, CH.sub.3(CH.sub.2).sub.16CO--, CH.sub.3(CH.sub.2).sub.18CO--, CH.sub.3(CH.sub.2).sub.20CO-- or CH.sub.3(CH.sub.2).sub.22CO--.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.